loading...| Preferred Name | metformin hydrochloride | |
| Synonyms |
Glumetza Metformin HCl Dimefor Glifage Glucophage Fortamet N,N-dimethylimidodicarbonimidic diamide monohydrochloride Riomet Glucophage XR Siofor Cidophage Glucoformin 1,1-dimethylbiguanide hydrochloride |
|
| Definitions |
The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29251" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29251" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000593641 |
|
| altLabel |
Glumetza Metformin HCl Dimefor Glifage Glucophage Fortamet N,N-dimethylimidodicarbonimidic diamide monohydrochloride Riomet Glucophage XR Siofor Cidophage Glucoformin 1,1-dimethylbiguanide hydrochloride |
|
| CAS Registry |
657-24-9 |
|
| cui |
C4053707 C0939699 C1330510 C1724447 C1602566 C4053702 C4053706 C0770893 C4053709 C4087008 C0591573 |
|
| DATE FIRST PUBLISHED |
2008-04-09 |
|
| Date last modified |
2015-11-05 |
|
| definition |
The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29251" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29251" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C29251 |
|
| notation |
CDR0000593641 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
metformin hydrochloride |
|
| tui |
T109 T121 |